More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...

FDA commissioner Marty Makary said it would be “magical” for consumers to see prescription drugs on pharmacy shelves instead ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

The FDA expedited drug review activity in December 2025 includes six fast-tracked therapies and the first National ...

Food and Drug Administration commissioner Marty Makary's flagship effort to overhaul how the agency reviews drugs is facing ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...